PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2020 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Sat - Aug 22      Sun - Aug 23      Mon - Aug 24      Tue - Aug 25   

TUESDAY, AUGUST 25

7:00 - 7:45 AM
SATELLITE SYMPOSIUM
OCTAPHARMA BREAKFAST SYMPOSIA: FINAL RESULTS FROM THE NUWIQ PUP STUDY: INHIBITOR RATES & BEYOND
Chicago Ballroom 7


SANOFI/GENZYME BREAKFAST SYMPOSIA: BREAKING THE BARRIERS IN HEMOSTASIS
Sheraton Ballroom

8:00 - 9:30 AM
HEMOSTASIS / BASIC SCIENCE
ADVANCES IN UNDERSTANDING BLEEDING DISORDERS
Chair/Organizer: Julie Jaffray, Roona Sinha
Chicago Ballroom 10


8:00

FVIII AND ITS ROLE AS THE GENETIC BASIS OF HEMOPHILIA
Chris Doering.


8:30

MODELING IMMUNE-MEDIATED THROMBOCYTOPENIA: INSIGHTS ON MECHANISMS
Heyu Ni. University of Toronto / Canadian Blood Services Centre for Innovation


9:00

GENOTYPE/PHENOTYPE DISCREPANCIES IN RARE BLEEDING DISORDERS
Diane Nugent. CHOC Childrens Hospital/UC Irvine and Center for Inherited Blood Disorders

8:00 - 9:30 AM
THROMBOSIS
ANTICOAGULATION STEWARDSHIP
Chair/Organizer: Stacy Ellsworth, Maury Lieberman
Sheraton Ballroom 1


8:00

THE FUTURE OF ANTICOAGULATION CLINICS AND ROLE OF CLINICIANS
Arthur Allen. VA Salt Lake City Health Care System


8:30

ESTABLISHING AN ANTICOAGULATION STEWARDSHIP PROGRAM (REVIEW OF FDA/TJC STANDARDS AND AC FORUM GUIDANCE)
Scott Kaatz. Henry Ford Hospital


9:00

ANTICOAGULATION STEWARDSHIP PROGRAMS (EXAMPLES OF EXCELLENCE)
Anne Rose. UW Health

8:00 - 9:30 AM
LABORATORY
UPDATE ON LABORATORY TESTING FOR ACQUIRED DISORDERS
Chair/Organizer: Joyce Rodgers, Dot Adcock
Sheraton Ballroom 5


8:00

UPDATE ON TESTING FOR AUTOANTIBODIES IN ACQUIRED HEMOPHILIA
Ken Friedman. Versiti - Bloodcenter of Wisconsin


8:30

LABORATORY EVALUATION OF ACQUIRED VON WILLEBRAND DISEASE
William Nichols. Mayo Clininc - Rochester, MN


9:00

LABORATORY APPROACH TO MONITORING COAGULATION DURING LIFE SUPPORT
Oksana Volod . Cedars Sinai Medical Center

9:30 - 10:30 AM
SHORT TALKS
BLEEDING DISORDER THERAPY AND OUTCOMES
Chicago Ballroom 6


INCREASED HEMOPHILIA-RELATED DISTRESS IS ASSOCIATED WITH REDUCED ADHERENCE TO FACTOR REPLACEMENT THERAPY.
Sara A. Guasch1, Janet Figueroa 1, Vaughn Barry1, Shanna Mattis1, Tyler W. Buckner2, Duc Q. Tran1, Stephanie Whitten 1, Christine L. Kempton 1. 1Emory University, Atlanta, GA, USA. 2University of Colorado, Aurora, CO, USA


PATIENTS WITH G-HSD/HEDS EVALUATED AT HTCS HAVE SIMILAR CO-MORBIDITES TO THOSE IN THE GENERAL POPULATION
Rohith Jesudas1, Christopher Eberlin2, Sweta Gupta3, Amit Soni4, Diane Neugent4, Nina Hwang4, Vanessa Salinas4, Nicole Crook4, Ateefa Chaudhury4, Christina Laukaitis5. 1Bleeding and clotting disorders institute, Peoria, IL, USA. 2University of Illinois College of Medicine in Peoria, Peoria, IL, USA. 3Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA. 4Center for Inherited Blood Disorders, Orange, CA, USA. 5University of Arizona, Tucson, AZ, USA


HEMATOLOGY PROVIDER ATTITUDES AND PRACTICES REGARDING IUD INSERTION IN ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING WITH AND WITHOUT BLEEDING DISORDERS
Allison Wheeler1, Katherine O'Flynn O'Brien2, Claudia Borzutzky3, Peter Kouides4, Oluyemisi Adeyemi-Fowode2. 1Vanderbilt University Medical Center, Nashville, TN, USA. 2Texas Children's Hospital, Houston, TX, USA. 3Children's Hospital of Los Angeles, Los Angeles, CA, USA. 4Mary M Gooley Hemophilia Treatment Center, Rochester, NY, USA


INHERITED AND ACQUIRED BLEEDING DISORDERS
Chicago Ballroom 7


SECOND-LINE THERAPY WITH FOSTAMATINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
Ralph Boccia1, Waleed Ghanima2, Quentin Hill3, Michelle Sholzberg4, Michael D Tarantino5, Darla Liles6, Yuliya Kreychman7, Robert P Numerof7, Sonia Souza7, Leslie Todd7, Sandra Tong7, James B Bussel8. 1Center for Cancer and Blood Disorders, Bethesda, MD, USA. 2Department of Research, Ostfold Hospital Trust, Sarpsborg and Department of Hematology, Institute of Clinical Medicine, Sarpsborg, Norway. 3Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 4Li Ka Shing Knowledge Institute, St. Michael, Toronto, ON, Canada. 5The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA. 6East Carolina University Brody School of Medicine, Greenville, NC, USA. 7Rigel Pharmaceuticals, Inc, South San Francisco, CA, USA. 8New York Presbyterian Hosp. Weill Cornell Medical Center, New York, NY, USA


SCREENING FOR FACTOR IX PADUA (R338L) IN PEDIATRIC THROMBOSIS PATIENTS
Benjamin J Samelson-Jones1, 2, 3, James F. Jarrett III1, Leslie J. Raffini1, 2, Valder R. Arruda1, 2, 3. 1The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, USA


ASSESSMENT OF RARE BLEEDING DISORDERS IN ADOLESCENT FEMALES WITH UNEXPLAINED BLEEDING
Ruchika Sharma1, 2, Seema Menon2, Michelle Dobratz1, Bridgit Hansen1, Victoria Johnson1, Veronica Flood1, 2. 1Versiti Blood Center of Wisconsin, Milwaukee, WI, USA. 2Medical College of Wisconsin, Milwaukee, WI, USA


PLATELETS AND VON WILLEBRAND FACTOR
Chicago Ballroom 9


THE (F)UTILITY OF SCREENING FOR ACQUIRED VON-WILLEBRAND DISEASE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.
Jasmina Ahluwalia 1, Saniya Sharma1, Narender Kumar1, Varun Uppal1, Anita Kler1, Neelam Varma1, Arihant Jain2, Pankaj Malhotra2. 1 Dept of Hematology, Postgraduate Institute of Medical Education a Research, Chandigarh, India. 2 Dept of Internal Medicine , Postgraduate Institute of Medical Education a Research, Chandigarh, India


ADVERSE BONE HEALTH AND WOUND HEALING OUTCOMES IN VON WILLEBRAND DISEASE
Divyaswathi Citla Sridhar1, 3, Yazan Abou-Ismail2, 3, Maria Pereda1, 3, Lalitha Nayak2, 3, Robert Sidonio Jr4, Sanjay Ahuja1, 3. 1Rainbow Babies a Children's Hospital, Cleveland, OH, USA. 2University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 3Case Western Reserve University, Cleveland, OH, USA. 41Children, Atlanta, GA, USA


GENOTYPE VS PHENOTYPE:A CROSS-SECTIONAL STUDY EXAMINING THE INCIDENCE OF GENETIC VARIANTS IN PATIENTS WITH QUALITATIVE PLATELET DISORDERS
Kristina/M Haley, Stewart Worthington, Susan Lattimore, Mary Pat Bland, Jody Kujovich. Oregon Health a Science University, Portland, OR, USA


PLATELETS AS VERSATILE EFFECTORS OF THROMBOINFLAMMATION IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS
Anandi Krishnan1, Wenfei Du2, Cecelia Perkins3, Zhu Shen4, Jason Gotlib5, James Zehnder6. 1Pathology, Stanford, CA, USA. 2Statistics, Stanford, CA, USA. 3Hematology, Stanford United States. 4Statistics, Stanford, CA, USA. 5Hematology, Stanford, CA, USA. 6Hematology, Stanford, CA, USA


THROMBOSIS: RISKS
Chicago Ballroom 10


INCREASED RISK OF THROMBOSIS IN ALK-REARRANGED LUNG CANCER
Hanny Al-Samkari1, 2, Orly Leiva2, 3, Ibiayi Dagogo-Jack1, 2, Alice Shaw1, 2, Pavan K. Bendapudi1, 2, Jean M. Connors2, 4. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA. 3Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 4Hematology Division, Brigham and Women's Hospital, Boston, MA, USA


EFFECT OF RACE/ETHNICITY ON THE RISK OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM FOR THREE COMMON CANCERS
Tatini Datta, Ann Brunson, Anjlee Mahajan, Theresa Keegan, Ted Wun. Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA


LOW BLEEDING RISK PROCEDURES: SHOULD WE LET DOAC BE?
Muhammad A. Sheikh1, Xiaowen Kong2, Brian Haymart2, Xiaokui Gu2, Scott Kaatz3, Gregory Krol3, Jay Kozlowski4, Musa Dahu5, Mona Ali6, Steven Almany7, Eva Kline-Rogers2, James Froehlich2, Geoffrey D. Barnes2. 1Division of Hospital Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 3Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA. 4Department of Cardiovascular Medicine, Huron Valley Sinai Hospital, Commerce Township, MI, USA. 5Heart and Vascular Institute, Spectrum Health System, Grand Rapids, MI, USA. 6Department of Pharmacy, Beaumont Hospital, Royal Oak, MI, USA. 7Department of Internal Medicine, Beaumont Health, Oakland University School of Medicine, Royal Oak, MI, USA


CREATION OF A REAL-TIME RISK PREDICTION MODEL FOR PEDIATRIC THROMBOSIS EVENTS
Shannon C. Walker1, C. Buddy Creech1, Henry J. Domenico2, Daniel W. Byrne2, Allison P. Wheeler1, 2. 1Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA. 2Vanderbilt University Medical Center, Nashville, TN, USA

10:30 - 11:15 AM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


139

DIGITAL MONITORING OF PHYSICAL ACTIVITY VIA APP QUESTIONNAIRES IN PATIENTS WITH BLEEDING DISORDERS.
Marc Lara1, Suchitra Acharya2, Joseph Stanco2, Maissaa Janbain3, Amina Rafique3, Angela Kellum3, Robert Sidonio4, Guy Young5, Michael Callaghan6, Meera Chitlur6. 1MicroHealth, Inc, New York, NY, USA. 2Northwell Health, New York, NY, USA. 3Tulane University School of Medicine, New Orleans, LA, USA. 4Children's Healthcare of Atlanta, Atlanta, GA, USA. 5Children's Hospital of Los Angeles, Los Angeles, CA, USA. 6Children's Hospital of Michigan, Detroit, MI


140

DOES DISTANCE TO HEMOPHILIA TREATMENT CENTER IMPACT USE OF HEMOPHILIA TREATMENT SERVICES?
Susan U Lattimore, Alysia Cox, Kristina M Haley, Madolyn T Hofstetter, Kelsey Smith. Oregon Health a Science University, Portland, OR, USA


141

DESIGN OF TWO NEW GENE THERAPY VECTORS FOR HEMOPHILIA A AND HEMOPHILIA B
Franziska Horling1, Johannes Lengler1, Dan Sexton2, Werner Hoellriegl1, Friedrich Scheiflinger1, Hanspeter Rottensteiner1. 1Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 2Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA


142

DESIGN OF A GLOBAL, OPEN-LABEL PHASE 1/2 STUDY INVESTIGATING THE SAFETY AND DOSE OF TAK-754, AN INVESTIGATIONAL FACTOR VIII GENE THERAPY, IN PATIENTS WITH SEVERE HEMOPHILIA A
Natalia Holot1, Bruce Ewenstein2, Joseph Gao2, Mila Ayash-Rashkovsky2. 1Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA. 2Baxalta US Inc, a Takeda company, Cambridge, MA, USA


143

TAKE CONTROL. PERIOD. - NEEDS ASSESSMENT LEADING TO THE DEVELOPMENT OF A DIGITAL QUALITY IMPROVEMENT INTERVENTION DESIGNED TO ENHANCE ADHERENCE TO TRANEXAMIC ACID AND IRON SUPPLEMENTATION IN WOMEN WITH HEAVY MENSTRUAL BLEEDING
Ying Ling1, Filomena Meffe2, Deborah Robertson2, Jessica Petrucci3, Georgina Floros3, Paula James4, Jeffrey Mosko5, Michelle Sholzberg3, 6. 1Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Department of Obstetrics and Gynecology, St. Michael, Toronto, ON, Canada. 3Division of Hematology/Oncology, Department of Medicine, St. Michaels Hospital, Toronto, ON, Canada. 4Division of Hematology, Department of Medicine, Queen, Kingston, ON, Canada. 5Division of Gastroenterology, Department of Medicine, St. Michael, Toronto, ON, Canada. 66Department of Laboratory Medicine and Pathology, St. Michael, Toronto, ON, Canada


144

ENDOGENOUS THROMBIN POTENTIAL (ETP) IS SIGNIFICANTLY MORE ENHANCED BY EMICIZUMAB IN THROMBIN GENERATION ASSAY (TGA) PERFORMED WITH PLATELET RICH PLASMA (PRP) AS OPPOSED TO PLATELET POOR PLASMA (PPP)
Erika J Martin1, Gita V Massey2, Janice G Kuhn1. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children, Richmond, VA, USA


145

EMICIZUMAB AND TRAUMA: CASE REPORT OF FRACTURE, FASCIOTOMY AND SKIN GRAFTING IN A HEMOPHILIA PATIENT WITH HIGH TITER INHIBITOR
Daniel Choi, Maria Teresa DeSancho, Jeffery Laurence, Ilene Goldberg, Catherine McGuinn. Weill Cornell Medicine, New York, NY, USA


146

HEPARIN RESISTANCE IS COMMON IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
Vikram Raghunathan1, 2, Patricia Liu2, Joseph Shatzel1, 2, 3. 1Division of Hematology and Oncology, Oregon Health a Science University, Portland, OR, USA. 2Department of Medicine, Oregon Health a Science University, Portland, OR, USA. 3Department of Biomedical Engineering, Oregon Health a Science University, Portland, OR, USA


147

A PHASE 3B, OPEN-LABEL, MULTICENTER, CONTINUATION STUDY OF RURIOCTOCOG ALFA PEGOL PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A: CLINICAL OUTCOMES IN PATIENTS WITH TARGET JOINTS BY AGE GROUP
Pratima Chowdary1, Eric Mullins2, Barbara A Konkle3, Catherine McGuinn4, Young Shil Park5, Oleksandra Stasyshyn6, Bulent Zulfikar7, Huyen Tran8, Werner Engl9, Srilatha Tangada10. 1Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. 2University of Cincinnati College of Medicine and Cancer and Blood Diseases Institute, Cincinnati Children, Cincinnati, OH, USA. 3Bloodworks Northwest and the University of Washington, Seattle, WA, USA. 4Weill Cornell Medical College, New York, NY, USA. 5Kyung Hee University Hospital at Gangdong, Seoul, South Korea. 6Academy of Medical Sciences of Ukraine, Lviv. 7Department of Pediatric Hematology, Istanbul University Oncology Institute, Istanbul, Turkey. 8The Alfred Hospital, Melbourne, Australia. 9Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 10Baxalta US Inc, a Takeda company, Cambridge, MA, USA


148

LABORATORY CORRELATION OF THROMBIN GENERATION DATA, INCLUDING FACTOR VIII AND IX SENSITIVITIES ON AN AUTOMATED (ST GENESIA) VS. SEMI-AUTOMATED (CAT) PLATFORM
Steven Mcbryant1, Christian Nenninger1, Paul W Riley2, Mary Robinson1, Stefan Tiefenbacher1. 1Esoterix Inc. /Colorado Coagulation / A LabCorp Company (Laboratory Corporation of America Holdings), Englewood, CO, USA. 2Diagnostica Stago, Inc, Parsippany, NJ, USA


149

PHASE 2 CONCIZUMAB POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSES: APPLICATION TO PHASE 3 DOSE SELECTION
Trine Hoyer Rose, Christian Hollensen, Henrik Agerso, Steen Hvass Ingwersen, Rune Viig Overgaard. Novo Nordisk A/S, Soborg, Denmark


150

PULMONARY HEMORRHAGE AS A COMPLICATION OF TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: AN INSTITUTIONAL EXPERIENCE
Sarah Sartain 1, Stacey Shubert2, Caridad Martinez2. 1Department of Pediatrics, Section of Hematology-Oncology, Texas Children, Houston, TX, USA. 2Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children, Houston, TX, USA


151

EFFICACY AND SAFETY OF FIBRINOGEN CONCENTRATE FOR ON-DEMAND TREATMENT OF ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN PEDIATRIC PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Bruce. A Schwartz1, Flora Peyvandi2, Sunil. D Lohade3, Fulton D'Souza4, G. S Latha5, Claudia Khayat6, Omid Zekavat7, Irina Kruzkhova8, Cristina Solomon8, Sigurd Knaub8. 1Clinical Research a Development, Octapharma, Hoboken, NJ, USA. 2Fondazione IRCCS CaGrandaOspedaleMaggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy. 3Sahyadri Specialty Hospital, Pune, India. 4St. John, Bangalore, India. 5S. S Institute of Medical Science and Research Center, Davangere, India. 6Hotel De Dieu de France, Beirut, Lebanon. 7Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran. 8Research a Development Department, Octapharma, Lachen, Switzerland


152

SINGLE-DOSE PHARMACOKINETICS OF FIBRINOGEN CONCENTRATE FOR ON-DEMAND TREATMENT OF ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN PEDIATRIC PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Bruce. A Schwartz1, Flora Peyvandi2, S. D Lohade3, Fulton D'Souza4, G. S Latha5, Claudia Khayat6, Omid Zekavat7, Irina Kruzhkova8, Cristina Solomon8, Sigurd Knaub8. 1Clinical Research a Development, Octapharma, Hoboken, NJ, USA. 2Fondazione IRCCS CaGrandaOspedaleMaggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy. 3Sahyadri Specialty Hospital, Pune, India. 4St. John, Bangalore, India. 5S. S Institute of Medical Science and Research Center, Davangere, India. 6Hotel De Dieu de France, Beirut, Lebanon. 7Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran. 8Research a Development Department, Octapharma, Lachen, Switzerland


154

A NOVEL PATHOGENIC VARIANT WITHIN THE FACTOR XIII ACTIVE SITE PRESENTING AS SEVERE UMBILICAL HEMORRHAGE
Kaitlin L. Strumph, Jennifer G. Davila, William B. Mitchell. Division of Hematology/Oncology, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA


155

EFFICACY AND SAFETY OF BAY 94-9027 PROPHYLAXIS IS SUSTAINED FOR UP TO >2 YEARS: OUTCOMES IN 23 PATIENTS AGED ≥12 YEARS IN THE PROTECT KIDS STUDY AND EXTENSION
Sanjay Ahuja1, Jonathan M. Ducore2, Olubunmi Afonja3, Maria Wang3, Bryce A. Kerlin4. 1Rainbow Babies a Children, Cleveland, OH, USA. 2University of California Davis Medical Center, Sacramento, CA, USA. 3Bayer, Whippany, NJ, USA. 4Nationwide Children's Hospital, Columbus, OH, USA


156

INDEPENDENT EVALUATION OF A NEW CHROMOGENIC FACTOR VIII ASSAY KIT
Julie I. Tange, Nahla Heikal, Dong Chen, Rajiv Pruthi. Comprehensive Hemophilia Center and Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


157

RAPID DIAGNOSIS OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) USING A NEW FULLY-AUTOMATED CHEMILUMINESCENT ASSAY FOR ADAMTS13 ACTIVITY.
Pierre A Toulon1, Ines Harzallah2. 1Pasteur University Hospital, Hematology, Nice, France. 2Regional Hospital, Hematology, Mulhouse, France


158

THE HEMOSTATIC AND FIBRINOLYTIC ABNORMALITIES IN TRAUMA-INDUCED COAGULOPATHY
Mark Walsh, MD1, Hau C. Kwaan, MD2, Jordan Hatch, BS3, Faran Bokhari, MD, FACS4, Scott Thomas, MD5. 1St. Joseph Regional Medical Center, Mishawaka, IN, USA. 2Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3Indiana University School of Medicine, South Bend, IN, USA. 4John H. Stroger, Jr. Hospital, Chicago, IL, USA. 5Beacon Health Systems, South Bend, IN, USA


159

PULMONARY VEIN THROMBOSIS ASSOCIATED WITH A LARGE HIATAL HERNIA
Yu Zhao, Reynold Andika, Richard Alweis. Rochester Regional Health/Unity Hospital, Rochester, NY, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


160

TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR AHP, IN THE ENVISION OPEN LABEL EXTENSION
John P. Smith. University of Utah, Salt Lake City, UT, USA


161

PROGNOSTIC CATEGORISATION OF AML PATIENTS BASED ON CD7 AND CD56 EXPRESSION-A TERTIARY CARE CENTER STUDY IN NORTHERN INDIA
Sandeep Rai1, Prof Ritu Gupta2, Saroj Singh3. 1Lab Oncology, AIIMS, New Delhi, India. 2Lab Oncology, AIIMS, New Delhi, India. 3Lab Oncology, AIIMS, New Delhi, India

11:15 - 12:30 PM
PLENARY SESSION
PLENARY SESSION 3 & CLOSING REMARKS
Chair/Organizer: Robert Sidonio, Cathy Hayward
Sheraton Ballroom


11:15

PLENARY TALK
Jesse Roach.


11:40

CHOOSING BETWEEN NEW AND OLD THERAPIES FOR THROMBOSIS
Stephan Moll. Unviersity of North Carolina School of Medicine


12:05

ENSURING THE BEST CARE FOR PATIENTS WITH CONGENITAL AND ACQUIRED BLEEDING PROBLEMS. WHAT ARE OUR CHALLENG
Amy Shapiro. Indiana Hemophilia a Thrombosis Center